Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Abbott, Genentech Form Cancer Pact
July 2, 2007
| A version of this story appeared in
Volume 85, Issue 27
Abbott Laboratories and Genentech have formed a collaboration for the research, development, and commercialization of two of Abbott's investigational cancer compounds, known as ABT-263 and ABT-869. The small-molecule compounds, discovered by Abbott scientists, are being described as targeted therapies that promise unique approaches to treating cancer. ABT-263 is a Bcl-2 family protein antagonist that restores apoptosis, or cell death, in cancer cells. ABT-869 is a kinase inhibitor that stops tumors from growing by preventing the growth of blood vessels that supply them.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter